Locations:
SearchAdvertisement
Oral anticoagulants may be beneficial but need to be balanced against bleeding risks
Findings have implications for reducing venous thromboembolisms
A cost-effective alternative to enoxaparin?
An underappreciated immune-related adverse event
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Why routine screening isn’t advised despite higher prevalence of venous thromboembolism
Expert insights and a thromboprophylaxis protocol
Implementing order sets and protocols for managing obstetric emergencies
Add prophylaxis for patients receiving systemic therapy
Prescreening for clots also effective
The future of VTE risk prediction in cancer
Advertisement
Advertisement